However, due to the relatively small proportion of CBF cases in the ihCAMs‐AML cohort, this trend did not significantly impact the overall CR rate and did not influence the survival outcomes (OS and EFS) across the three UAMOCS subtypes. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.